Stockreport

Novo downgraded at J.P. Morgan as next-gen obesity drug trails Lilly's Zepbound [Seeking Alpha]

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF trial data indicating that its next-gen weight loss therapy CagriSema trailed Eli Lilly's ( LLY ) GLP-1 therapy tirzepatide, marketed as Zepbound Citing data from its [Read more]